Details of the Drug
General Information of Drug (ID: DM23E0R)
Drug Name |
4-Inden-(1E)-ylidenemethyl-phenylamine
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
4-(1H-Inden-1-ylidenemethyl)aniline; NSC83092; 4-[(E)-inden-1-ylidenemethyl]aniline; CHEMBL193376; 487-61-6; 1-(4-Aminobenzylidene)indene; p-Toluidine, .alpha.-inden-1-ylidene-; 4-(1H-Inden-1-ylidenemethyl)phenylamine; Benzenamine, 4-(1H-inden-1-ylidenemethyl)-; MLS002694146; WLN: L56 BYJ BU1R DZ; 4-Inden-(1E)-ylidenemethyl-phenylamine; AC1O53IW; AC1Q1HQ2; cid_98148; BDBM50164749; NSC-83092; AKOS030547084; ZINC100425076; NCGC00186285-13; NCGC00186285-07; NCGC00186285-06; NCGC00186285-01; NCGC00186285-11; NCGC00186285-09
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 219.28 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 3.6 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 1 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||